A 10-year clinical outcome of radiotherapy as an adjuvant or definitive treatment for primary tracheal adenoid cystic carcinoma

Tracheal cancer is a rare neoplasm that accounts for only 2% of upper airway tumors [1]. The incidence of primary tracheal tumors is <0.2 per 100,000 persons per year in the United States [2]. Squamous cell carcinoma (SCC) is the most common histological type of tracheal malignancy, followed by adenoid cystic carcinoma (ACC) [3, 4]. Tracheal ACC was first reported by Morgagni in 1762. ACC of the trachea and bronchi arises from glands in the tracheobronchial mucosa. ACC is characterized by slow growth, and distant metastasis has been reported as late as 25 years after diagnosis [5‐7].

Surgery is considered as the treatment of choice for ACC, and most articles have focused on the surgical outcome. Radiotherapy (RT) was traditionally used as an adjuvant treatment for controlling microscopic disease or as a salvage treatment for unresectable disease; however, the exact role of RT remains unclear due to the rarity of such reports. Although a few studies have described the use of surgery followed by adjuvant therapy, only a few factors related to RT planning or dose have been described [7‐9]. In particular, for definitive RT, additional information should be provided, as most retrospective studies thus far have analyzed a very small number of patients, have used a classical RT technique or irradiated a relatively lower RT dose [6, 8, 10, 11]. The most recently available data on modern RT techniques are described in case reports, and these provide promising results for RT of ACC of the trachea [12‐14].

In the present study, we aimed to evaluate the role of RT with modern techniques as adjuvant treatment after surgical resection or as definitive treatment in inoperable settings for primary tracheal ACC for local tumor control and survival.

Between November 1994 and December 2008, a total of 25 patients were treated with RT for pathologically confirmed primary ACC of the cervical or upper thoracic airway in our institution. We retrospectively reviewed the medical records and the study was approved by the institutional review board of Asan Medical Center, Seoul, Korea (AMC-IRB, 2012–0470). Tumor location was assessed by using a bronchoscope or computed tomography (CT), and cases with tumors located in the trachea and carina with/without main bronchus involvement were included in the study. The epicenters of primary tumor in all patients were trachea. We excluded patients with a distant metastasis prior to treatment. However, 1 patient with single lung metastasis at the initial diagnosis was included in this study, because the metastatic lesion had been successfully treated with stereotactic body radiotherapy and complete remission was achieved in that case.

The tracheal tumor stage was determined according to the staging system for primary tracheal malignancies proposed by Bhattacharyya et al [4]. We measured tumor size by using a fiber-optic bronchoscope or CT scan.

The eligibility for surgical excision was determined via a multidisciplinary conference or clinic, after reviewing the results of diagnostic studies and the patient’s condition. A dedicated thoracic surgeon determined the surgical approach and extent.

Adjuvant RT was usually initiated 4–6 weeks after surgery, and the standard dose was 50.4 Gy for 28 fractions. A boost dose was provided if the tumor had a surgical margin. Approximately 60–66 Gy of conventional fractionation was the standard dose for definitive RT, although brachytherapy (BT) was occasionally adopted for a local boost. In all cases of RT, a linear accelerator with three-dimensional conformal RT or intensity-modulated RT (IMRT) was used, and an iridium-192 high-dose BT system was employed. BT was conducted at 1 cm from the iridium source, and a boost dose of 15 Gy or 21 Gy with 5–7 Gy per fraction was used. The initial irradiation field encompassed the tumor or tumor bed as well as the adjacent mediastinal or supraclavicular lymph nodes in most patients. Clinical target volume (CTV) was usually expanded 3 cm in longitudinal from tumor bed or primary tumor and adjacent lymph node stations were included it at designated level. Planning target volume (PTV) was generally expanded 1 cm in both longitudinal and axial from the CTV. Dose constraints for organ at risk (OAR) like esophagus, lung or other organs were not absolutely determined in this study, while we tried not to produce hot-spot at esophagus due to the proximity to PTV and institutional dose constraint for whole lung was V20 < 30%.

In the definitive RT group, we judged tumor response according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria [15]. Response evaluation and routine follow-up was performed by CT images and bronchoscopy with/without biopsy was added to confirm residual tumor after definitive RT. Positron emission tomography (PET) was adopted in only a half patient, because it was not introduced in the early phase of this enrollment. PET was additionally used to confirm local progression or distant metastasis in some cases, but not routinely acquired. The initial response of RT was assessed at 1 or 2 months after RT. We used the Radiation Therapy Oncology Group (RTOG) toxicity grading system to score acute and chronic complications. Patients visited the outpatient clinic at 3-month intervals during the initial 2 years and at 6-month intervals thereafter.

The survival rate was calculated using the Kaplan-Meier survival analysis method. Survival curves were compared using the log-rank test and odds ratio from cox-regression analysis was calculated for multivariate analysis. All analyses were based on a two-sided test for significance (0.05), and were conducted using the SPSS Statistics 21.0 software (SPSS Inc., Chicago, IL).

Adenoid cystic carcinoma originally arises from the salivary glands and is a slowly progressing malignancy, with late metastasis to the lung, bone, and brain. The most common site in the airway is the trachea and the prognosis for ACC is better than that for SCC tracheal cancer [16, 17]. A few retrospective studies on the outcome of RT for tracheal ACC are summarized in Table 7. The studies mostly reported good 5-year OS of >70%; however, the results could not be directly compared with those of the current study, due to the lack of a definite consensus about the staging system for tracheal tumor and the difference in the treatment modalities.

In the present study, local recurrence was not observed in patients treated with PORT after surgical resection over a long follow-up duration, despite residual primary nidus after R1 resection in 11 (84.6%) patients. This clearly supports the role of RT for controlling microscopic disease in tracheal ACC. In contrast, there were 6 (66.7%) cases of LP in the definitive RT group. Hence, surgical resection of the tumor may be important for local tumor control, even though the tracheal tumor cannot be completely removed.

Nevertheless, definitive RT remains important in unresectable patients. Two-thirds of our study patients in definitive group lived for >5 years after RT, and the 10-year OS was 22.2%. Considering that these cases had relatively locally advanced tumors (T2 in 8 and T4 in 1 patient), this result does not appear to be disappointing, and hence, RT could be considered as an effective modality for unresectable tracheal ACC. Three patients developed LP more than 5 years after RT, which indicates that long-term evaluation with an appropriate imaging study should be recommended in these cases.

There is an issue in appropriate RT dose for unresectable tracheal ACC, but there is no consensus. In this study, patients treated with higher RT dose via BT boost had better long-term local tumor control and survival than those of patients receiving relatively lower RT dose. A 5 yr.-OS in patients treated with higher RT dose was very high, 88.3%. A 5 yr.-local control was 100% in 6 patients with higher RT dose, while all 3 patients with lower RT dose suffered from LP within 5 years after treatment (Fig. 1). Although this result was obtained from small number of patients (n = 9), it is sufficient to explain the necessity of escalated RT dose to sterilize gross tracheal ACC. We expect the IMRT can be a troubleshooter for escalating RT dose without additional treatment-related side effect, even if we used BT boost in most patients of this study that was done in period prior to clinical application of IMRT.

About 50% of ACC patients might eventually develop distant metastases, although regional lymph node involvement is reported to have been rare in several cohorts [6, 18]. In our present study, the main pattern of failure was distant metastasis. No regional lymph node metastasis was observed before or after treatment in our cases, but distant metastasis occurred in 63.6% of patients; the lung was the main metastatic site. The time interval between treatment and distant metastasis ranged from 8.4 to 91 months. Although a patient may develop a distant metastasis, they could remain alive with the metastasis for a long duration (up to 232 months); this may be related to the slow progression of ACC. The mean time interval from DM to death was 78 months, whereas the mean time interval between LP and death was 23 months in our series. This finding suggests that active local control can increase survival, although there is a risk of minimal distant metastasis in patients with tracheal ACC.

More than half of the patients in our present study lived for >5 years after definitive RT. Although this survival rate is inferior to that of the PORT group, it is sufficient to offer a feasible solution for patients with unresectable tracheal ACC. Nevertheless, LP developed between 5 years and 10 years after RT in 3 cases, and hence, the presence of symptoms in the airway should be monitored and proper imaging studies should be conducted for at least 10 years. The 10-year LPFS rate decreased to 26.7% in the present study cohort, and none of our patients exhibited LP after 10 years.

After resection with/without RT for tracheal cancer, some patients have been reported to develop severe complications such as recurrent laryngeal nerve palsy, tracheal stenosis, dysphagia, and airway granulation [6, 19‐21]. In the present study, 2 patients developed tracheal stenosis, which resulted in death. Hence, the risk of tracheal stenosis should be carefully considered when determining the RT plan or dose in both PORT or definitive RT. Moreover, we should consider a suitable intervention for resolving the symptoms of stenosis, including the growth of granulation tissue [22].

In the current study, we enrolled a small number of patients over a period of 14 years, and analyzed the data retrospectively. However, we followed up patients over a mean period of 10 years and primarily assessed them based on the use of RT. Hence, we could readily determine that patients with unresectable tracheal ACC could survive for a long duration after definitive RT.

In summary, tumor stage and surgical excision might be important factor for survival or local tumor control. However, considering the high possibility of residual disease after surgical resection, postoperative adjuvant RT should be considered to sterilize microscopic tumors after surgery for tracheal ACC. Moreover, unresectable tracheal ACC can effectively be treated with definitive radiotherapy, which yields relatively long-term survival (>5 years) in most patients. Especially in patients with high-dose RT, definitive RT can warrant long-term survival and local tumor control over 5 years with proper methods for beam delivery like IMRT or BT. The major pattern of failure was lung metastasis, regardless of whether surgery was performed. However, tracheal stenosis remains a major concern after RT, and the RT plan or dose should accordingly be adjusted in some patients.

Adjuvant radiotherapy for controlling microscopic residual disease in ACC may be suitable in cases of surgically resected tumors, whereas definitive radiotherapy may yield long-term survival in more than 50% of patients with unresectable tracheal ACC. Dose escalation should be considered to warrant long-term survival in definitive RT.